Introduction
The p53 tumour suppressor gene is frequently mutated in a variety of human cancers (Greenblatt et al., 1994) . The prevalent genetic abnormalities are missense mutations which generally give rise to full-length but distorted versions of the p53 protein. The amino acid (aa) residues within p53 most often targeted by the mutagenic process are thought to be normally involved in either directly contacting DNA or stabilizing the structure of the DNA binding surface, giving rise to the respective terms`contact' and`structural' p53 mutants (Cho et al., 1994) . Mutation of these critical residues results in severe impairment of the sequencespeci®c DNA binding activity and, as a consequence, the transcriptional activation function of p53 . p53 mutants often occupy a dierent conformational state in comparison to the wt protein, as indicated by altered binding to p53-speci®c antibodies and a selection of viral and cellular proteins . This mutationinduced change in conformation, which varies depending on the location and type of amino acid substitution, is thought to be due to either partial or widespread unfolding of the p53 protein.
Many common tumour-derived p53 mutants display distinct oncogenic properties, the classic example being co-operation with an activated ras gene to mediate neoplastic transformation of rat embryonic ®broblasts (REF) (Hinds et al., 1990) . The currently favoured explanation of this phenomenon is that the wt p53 pathway is overwhelmed by a dominant negative eect due to the formation of dysfunctional hetero-tetramers between mutant and wt p53 proteins (Milner and Medcalf, 1991) . On the other hand, the concept that p53 mutants can acquire additional oncogenic properties that are not dependent upon inhibition of wt p53, the so-called`gain of function' eect, is still controversial. Several studies have examined the impact on tumorigenesis caused by the introduction of p53 mutants into cells with a p53null background (Dittmer et al., 1993; Hsiao et al., 1994; Harvey et al., 1995; Gloushankova et al., 1997; Li et al., 1998) . In the absence of wt p53, certain p53 mutants can promote various aspects of tumorigenic behaviour such as morphological transformation, malignant conversion, genomic instability, cell growth, invasion and metastasis. Other p53 mutants are either limited with respect to these capabilities or do not illustrate any additional oncogenic properties which are independent of wt p53 inactivation. Mutant p53 is thought to exhibit another form of selective`gain of function' which appears to compromise the ecacy of conventional chemotherapy (Blandino et al., 1999) . In striving for more speci®c cancer therapies, it may thus be informative to carefully consider the relationship between a given p53 mutation and current therapeutic regimens. One intriguing possibility is the design of p53-oriented molecular therapies that target the`gain of function' phenotype itself (Gallagher and Brown, 1999) .
In this study, we set out to identify mutant p53-interacting protein partners through a yeast two-hybrid screening strategy with a common tumour-derived p53 mutant as bait (Fields and Song, 1989) . Our main aim was to obtain, and subsequently characterize, proteins which bound speci®cally to mutant, as opposed to wt, p53 protein. Characterization of such mutant p53-speci®c binding partners may help in deciphering the molecular basis of the`gain of function' phenotype.
Results

Identi®cation of mutant p53-interacting protein partners by yeast two-hybrid screen
The`hot-spot' human p53 mutant H175 was selected as the bait due to it being one of a subset of oncogenic p53 mutants that show evidence of a signi®cant change in conformation from that assumed by the wt protein . In creating the bait, the Nterminal transactivation domain of H175 was removed (Iwabuchi et al., 1993) , with the resulting H175D1 ± 72 mutant then being fused to the DNA binding (DB) domain of GAL4 [aa 1 ± 147]. When introduced on its own into the yCM17 yeast strain (Saltzman et al., 1998) , the GAL4(DB)-H175D1 ± 72 hybrid is incapable of activating transcription of either of the two reporter genes present, these being GAL1-URA3 and GAL10-LacZ. Before screening commenced, we con®rmed that the H175D1 ± 72 mutant bait was still capable of binding to full-length wt p53, itself having been fused to the transcriptional activation (TA) domain of GAL4 [aa 768 ± 881]. Thus, the modi®ed mutant p53 bait retains hetero-oligomerization capacity, a known biochemical activity of native H175. A commercially-available yeast two-hybrid cDNA expression library, containing at least 2.5 million independent cDNA species connected to the GAL4(TA) domain and derived from the human osteosarcoma cell line U2OS/HTB-96, was screened for cDNA clones encoding for fusion proteins that could interact with the H175D1 ± 72 mutant bait (Table 1) .
Over 7.5 million co-transformants, each having both the bait and an individual cDNA expression library clone within the same yeast cell, were screened. One hundred and seven of these exhibited the ability to grow in the absence of uracil (Ura), one of the reporter genes for assessing protein-protein interaction, as indicated above, being GAL1-URA3. However, only nine of the Ura + co-transformants subsequently displayed a signi®cant level of b-galactosidase (bgal) activity, the corresponding protein being produced by the other reporter gene GAL10-LacZ. More than half of the cDNA clones isolated from the Ura + bgal + cotransformants encoded for p53 polypeptides, these ranging in size from approximately 100 aa to the fulllength protein. None of the isolated p53 forms contained mutations as is expected since the U2OS/ HTB-96 cell line has p53wt status. All of the p53 forms retained the entire oligomerization domain, as seen before in an analogous yeast two-hybrid screen with wt p53 as the bait (Iwabuchi et al., 1993) . The isolation of wt p53 here provided us with initial con®rmation that the modi®ed mutant p53 bait could actually identify a physiologically relevant mutant p53-interacting protein partner using this particular screening procedure.
The other clones from the remaining Ura + bgal + cotransformants were separated into two batches, each of which contained a dierent cDNA species encoding for one of the following known proteins: (a) hUBC9, the human homologue of yeast ubiquitin-conjugating enzyme 9 (Shen et al., 1996) , and (b) GBP/PIAS1, a protein partner of Gu/RNA helicase II and speci®c inhibitor of STAT1 signalling (Valdez et al., 1997; Liu et al., 1998) . Both of these mutant p53-interacting protein partners were isolated more than once during the screening process. Protein-protein interaction between hUBC9 and wt p53 has already been reported prior to this study (Shen et al., 1996) . There is also some mention of an association between GBP/PIAS1 and wt p53 proteins, albeit this information is described solely within the relevant GenBank submission record (accession U38785). A related protein, PIASy, has recently been shown to be also capable of binding to wt p53 (Nelson and Maxwell, 1999) . In summary, our screen has identi®ed two additional mutant p53-interacting protein partners, apart from wt p53, which are known to bind p53. This provides added justi®cation for the use of the H175D1 ± 72 mutant as the bait, as apparently physiologically relevant targets with respect to p53 were again found.
In parallel to the afore-mentioned screen, the H175D1 ± 72 mutant bait was used to search a mouse cDNA expression library consisting of 2 million recombinant clones, having been derived by fusion of the GAL4(TA) domain with cDNA isolated from mouse embryos at day 14.5 (Chevray and Nathans, 1992). One particular plasmid was obtained on several independent occasions after screening around 6 million yeast co-transformants. Being a novel cDNA (no match found within the GenBank sequence database of mouse mRNA transcripts), the encoded protein was ascribed the label MBP1 ± standing for Mutant p53 Binding Protein 1. Interestingly, MBP1 was the only mutant p53-interacting protein partner which did not also exhibit signi®cant binding to wt p53D1 ± 72 in yeast ( Table 1 ). The other two mutant p53-interacting protein partners demonstrated either equal or greater, as in the case of hUBC9, binding speci®city for wt p53. PIASy, in a similar manner to GBP/PIAS1, binds just as eciently to the H175 mutant as to wt p53 (Nelson and Maxwell, manuscript in preparation).
As the remit of the investigation was to identify mutant p53-speci®c binding partners, we chose to focus on MBP1 in all further characterization studies.
Classi®cation of MBP1 as a new member of the ®bulin gene family A native translation initiation codon was not found downstream from the point of fusion between the yeast two-hybrid expression vector and the cloned MBP1 insert. We therefore rationalized that the cDNA insert However, the primary protein structures of both MBP1DN and H411 bear a striking resemblance to that found within members of the newly-established ®bulin gene family . In more detail, this novel protein shares a unique C-terminal region with S1-5, along with ®bulin-1 and ®bulin-2. Additionally, all of these proteins are characterized by the presence of several repeated epidermal growth factor (EGF)-like modules, most of which can bind calcium. EGF-like domains themselves are found within a variety of, mainly extracellular, proteins implicated in cell growth, development and cell signalling (Campbell and Bork, 1993) . Intracellular exceptions include certain cyclo-oxygenases and peroxidases (Toh et al., 1992) . While both ®bulin-1 and ®bulin-2 are known to be secreted, S1-5 protein may be dierentially localized, i.e. either retained within the cell or passed into the extracellular matrix (ECM). The ®nal destination of S1-5 protein appears dependent upon alternative splicing of RNA transcripts and/or the site of translation initiation chosen (Lecka-Czernik et al., 1995) . Since EGF-like domains are known to mediate protein-protein interactions, it is attractive to hypothesize that MBP1 might bind to mutant p53 through these domains.
Expression of MBP1 mRNA in the mouse embryo and in human adult tissues A polymerase chain reaction (PCR)-derived fragment of MBP1 cDNA was used as a probe in Northern blot analysis ( Figure 1) . A single 1.8 kb mRNA transcript was readily detected in mRNA prepared from either mouse embryos at dierent developmental stages ( Figure 1a ) or a selection of adult mouse tissues (Figure 1b) . Although MBP1 mRNA was found to be constitutively expressed, some variation was noticed in the absolute levels of transcript depending upon embryonic stage or tissue type. Early during development of the mouse embryo (day 7), MBP1 mRNA is abundantly expressed (Figure 1a ). By day 11 and afterwards, the level of MBP1 mRNA becomes markedly reduced. This suggests a link between MBP1 mRNA expression and cell growth, as the proliferative status of the majority of cells within the developing embryo tends to diminish with time. High levels of MBP1 mRNA were observed in adult lung and testis tissue (Figure 1b) . Moderate MBP1 mRNA expression was noted in the remaining tissues, with the exception of a low level of transcript in brain tissue. This expression pattern in mouse adult tissues is similar to that seen with murine S1-5, albeit with some minor dierences (Lecka-Czernik et al., 1995) . In summary, expression of MBP1 mRNA appears to be differentially regulated both temporally during development of the mouse embryo and in a tissue-speci®c manner within the adult.
Binding speci®city of MBP1DN for dierent p53 forms
As indicated above, while displaying a high anity for the H175D1 ± 72 mutant in yeast, MBP1DN shows no apparent speci®city for wt p53D1 ± 72. We therefore examined the binding anity of MBP1DN towards other tumour-derived p53 mutants ( Figure 2 ). These mutants were chosen so as to provide representative examples of two`contact' p53 mutants (H273 and W248), as well as an extra`structural' mutant (G281) apart from H175. As with wt p53 and H175, Nterminal deleted forms of the above p53 mutants were used in a two-hybrid interaction assessment ( Figure  2a ). In yeast, MBP1DN did not show any signi®cant binding to the H273 and W248 mutants, both of which are proposed to have conformations that are similar to the wt protein . A moderate level of interaction was observed between MBP1DN and the G281 mutant. This leads to the suggestion that MBP1DN has an order of speci®city with regard to binding of p53 mutants, which in turn appears to be related to the extent of conformational change of these mutants from wt p53. The same pro®le of MBP1DN binding speci®cities was observed when full-length mutant and wt p53 proteins were used ( Figure  2b ). Additionally, re-arrangement of GAL4(DB) and GAL4(TA) domains had no impact upon the dierential binding speci®city exhibited by MBP1DN towards these p53 variants.
Speci®c interaction between MBP1DN and mutant p53 in mammalian cells
We next sought to con®rm the interaction between MBP1DN and the H175 mutant in mammalian cells. H1299 cells (p53null), which are derived from a human lung carcinoma, were transiently co-transfected with myc-tagged MBP1DN plus either full-length H175 mutant or wt p53 cDNA expression constructs (Figure 3a) . Cell extracts were immunoprecipitated with antibodies speci®c for either the myc epitope (9E10) or the N-terminal portion of p53 (DO-1). Both antibodies illustrated co-immunoprecipitation of Figure 1 Expression of MBP1 mRNA in mouse embryo and adult tissues. RNA hybridization analysis of the levels of MBP1 mRNA found within two commercially available Northern blots ± (a) mouse embryo, dierent developmental stages (b) mouse adult, multiple tissue types. RNA loading was evaluated by hybridization with a GAPDH-speci®c probe. The relative abundance (RA) of MBP1 mRNA is expressed as a function of the GAPDH mRNA signal MBP1DN and H175. In addition, this interaction is speci®c for mutant p53 as MBP1DN showed no apparent anity for wt p53 protein in the same assay. The H175 mutant showed no evidence of signi®cant binding to SAM68, a non-relevant protein which is also myc-tagged (Figure 3b ). This con®rms that the myc epitope itself does not mediate the interaction between MBP1DN and mutant p53 protein.
The W248 and H273 mutants demonstrated minimal binding to MBP1DN (Figure 3c ). Although not illustrating the same high anity for MBP1DN as H175 does, the G281 mutant displayed an intermediate level of interaction which was considerably more elevated than that seen with the other two mutants. This data is again consistent with the hypothesis that high anity MBP1DN binding is mainly restricted to those p53 mutants such as H175, and to a lesser extent G281, which are largely dierent in structural terms from wt p53 . In summary, on the basis of both two-hybrid analysis in yeast and co-immunoprecipitation in mammalian cells, we propose the order of binding speci®city of MBP1 towards dierent p53 forms to be as follows: H1754G2814H2735W2484wt p53.
Neoplastic transformation and stimulation of tumour cell growth by MBP1DN
Subsequently, we examined the eect of MBP1DN expression on neoplastic transformation and tumour cell growth. First of all, MBP1DN was observed to cooperate with an activated ras gene to mediate REF transformation (Table 2 and Figure 4 ). The activated ras plus MBP1DN-induced foci were easily distinguished as circular areas of cells that are less densely populated than the surrounding monolayer. Microscopic examination revealed that the cells within these foci displayed a marked transformation in morphology from normal REF (Figure 4) . Stable cell lines could be isolated from single foci, a crucial test in the REF Figure 2 Binding speci®city of MBP1DN towards dierent p53 forms in yeast. Speci®city of interaction between MBP1DN and either (a) truncated or (b) full-length p53 variants. Yeast cells were co-transformed with the indicated combinations of both GAL4(DB) and GAL4(TA) hybrid constructs. Several independent co-transformants from each combination were spotted onto agar plates impregnated with growth medium. Co-transformants were examined either for the ability to grow in the absence of uracil or the extent of bgal activity present. (a) The solid medium either contained uracil (plus Ura) or did not (minus Ura). Cotransformants were left to expand, if able to, for several days. The apparently high anity interaction between MBP1DN and G281D1-72, i.e. signi®cant growth in the absence of uracil, was subsequently shown to be somewhat less emphatic than that seen with H175D1-72, as determined by secondary evaluation of bgal activity (data not shown). (b) Co-transformants were grown on solid medium until at exponential phase, transferred to nylon membranes and lysed by successive freeze-thawing. Membranes were then incubated with 1 mg/ml of X-Gal, a blue colour being produced upon hydrolysis of this substrate by bgal (Fields and Song, 1989) . The bgal controls were added to each blot to illustrate the extent of variation in the amount of bgal activity generated by either high anity protein-protein interactions, such as that seen between GAL4(DB)-H175D1-72 and GAL4(TA)-wt p53 (Ctrl + ), or total lack of reporter gene expression, as evidenced upon combination of GAL4(DB) and GAL4(TA) alone vectors (Ctrl 7 ). Although not shown here, W248 exhibited the same absence of bgal activity, when tested for binding to MBP1DN, as that seen with H273. With respect to the evidenced dierential MBP1DN binding speci®city towards full-length p53 variants, the same overall results were obtained when these cotransformants were tested for uracil dependence (data not shown) (Table 2 ). As would be expected for a gene that shows such co-operation with activated ras, expression of MBP1DN alone also mediated REF immortalization (data not shown). The above results provided the initial indication that MBP1 may have some inherent oncogenic activity. Interestingly, combination of MBP1DN and H175 cDNA expression plasmids proved to be more potent than either construct alone in mediating neoplastic transformation of REF, which appeared to be a synergistic rather than purely additive eect (Table 2) . No evidence of a synergistic eect was observed when MBP1DN was transfected in concert with ras-V12 plus c-myc, a control combination that also induces foci formation (data not shown).
Clonogenic survival assays were then performed using H1299 cells transfected with either empty vector or H175 mutant constructs plus increasing amounts of MBP1DN cDNA expression plasmid (Table 3 ). The H175 mutant on its own was completely defective in growth suppressor activity and showed no added ability to promote the growth of H1299 cells, which is in agreement with previously published results using this particular tumour cell line (Walker and Levine, 1996) . Transfection with MBP1DN cDNA expression plasmid alone produced a dose-responsive promotion of tumour cell growth, as exempli®ed by an increased number of H1299 colonies surviving compared to the vector alone control. When introduced together into H1299 cells, MBP1DN and the H175 mutant showed evidence of concerted action regarding the promotion of tumour cell growth (Table 3 ). In summary, MBP1DN displays both mutant p53-dependent and -independent oncogenic properties.
Isolation of full-length MBP1 cDNA
We recently cloned a full-length MBP1 mRNA transcript from an 8.5 day mouse embryo cDNA library using a PCR-based approach. Analysis of the primary structure of the predicted 443 aa protein revealed as expected the entire complement of six EGF-like domains that are found in H411, the candidate hamster homologue of MBP1 ( Figure 5) . In a similar fashion to H411, the N-terminus of the MBP1 protein also contains a putative topogenic sequence (TS), seen as a short region (27 aa) of mostly hydrophobic residues. Topogenic sequences de®ne protein tracking events and are found in proteins destined for either the secretory pathway or integration into the membranes of various subcellular organelles (Blobel, 1980) . The function of the N-terminal TS has been shown to depend on a balance between the length of the hydrophobic segment and the N-terminal charge (Sakaguchi et al., 1992) . According to our predictions based on this model, the putative TS within MBP1 is at the borderline between either a signal or signal-anchor type I sequence. The presence of a signal-anchor sequence of this type would insinuate MBP1 as being a type I membrane protein, i.e. with the C-terminal portion of the protein facing into the cytoplasmic side. A signal sequence would mean that MBP1 passes along the secretory pathway, most likely ®nding its terminal location within the ECM.
MBP1 exhibits similar oncogenic properties as N-terminal truncated form
Transfection of an expression vector containing the completed MBP1 cDNA into the H1299 cell line (Finlay, 1995) . Numbers of foci from 3 ± 4 independent experiments are shown, along with the average and standard error of the mean (s.e.m.). To ascertain whether the foci could be stably cloned, individual colonies from parallel transfections were trypsinized and grown in the presence of 400 mg/ml G418 (Figure 6a) . Interestingly, MBP1 appeared slightly more eective than MBP1DN at increasing the total number of surviving colonies in the clonogenic assay. This suggests that the upstream portion of MBP1 that is missing in the truncated form may further add to the oncogenic properties of the protein. It was also noted that the degree of oncogenic synergy with the H175 mutant remained approximately the same when either MBP1 form was used. Thus, the N-terminal domain of MBP1 does not appear necessary for this synergistic eect with mutant p53 to be obtained. Studies with full-length MBP1 revealed that it can also co-operate with activated ras in mediating neoplastic transformation of REF ( Figure  6b) . The activated ras plus MBP1-induced foci displayed the same type of morphological transformation as that seen with MBP1DN (data not shown). No signi®cant dierence between MBP1DN or its fulllength version with respect to this particular oncogenic Each experiment shows the total number of surviving colonies (containing 450 cells) remaining after drug selection per plasmid combination. The ®gures in parenthesis refer to the fold alteration in cell growth compared to the vector alone control within each experiment. An average of these values is also indicated, along with the standard error of the mean Figure 5 Amino acid sequence of full-length MBP1. The aa residues within H411 that dier from its mouse counterpart are shown underneath the main sequence. The putative N-terminal TS within MBP1 is shown in italics, with the signal peptidase cleavage site indicated by an inverted solid triangle (between aa 27 and 28). The six EGF-like domains are underlined, the start of each domain being demarcated by encircled numbers. All of these domains contain a calcium-binding consensus sequence. property was seen. Synergism between the entire form of MBP1 and mutant p53 with respect to neoplastic transformation was again observed. Therefore, the oncogenic properties shown by MBP1 are akin to those exhibited by its N-terminal truncated version.
Discussion
Active involvement of the ubiquitin-proteasome pathway in mediating degradation of the p53 protein is well-described (Schener, 1998) . This control of p53 protein levels is an important mechanism for regulating p53 activity. The binding of ubiquitin-conjugating enzymes such as hUBC9 to p53 has been observed before, with this type of protein-protein interaction perhaps being necessary for ecient p53 degradation to occur (Shen et al., 1996; Schener, 1998) . It is common knowledge that mutation of the p53 gene often results in the generation of stabilized mutant protein. The reduced anity of hUBC9 for the H175 mutant, in comparison to the wt protein, may re¯ect one potential mechanism whereby mutant p53 proteins have extended half-lives due to inecient degradation via the ubiquitin-proteasome pathway. There is accumulating evidence within the literature to suggest a relationship between p53 and the JAK-STAT signalling pathway. On the one hand, suppression of p53-mediated cell death by cytokines has been correlated with JAK-STAT activation (Quelle et al., 1998) . On the other hand, p53 itself appears to be capable of negatively regulating certain STAT proteins (Fritsche et al., 1998) . The observed binding of p53 to two members of a family of proteins which speci®cally inhibit STAT activity, GBP/PIAS1 and PIASy (Nelson and Maxwell, 1999) , might shed some light on the above processes. As both the H175 mutant and wt p53 exhibited similar binding anity towards GBP/PIAS1, no conclusions can be drawn as to the relevance of this interaction for mutant p53-associated activities.
MBP1 is a novel mutant p53-speci®c protein partner which displays enhanced oncogenic activity in the presence of mutant p53. Only a few proteins have so far been identi®ed which interact speci®cally with mutant p53 while simultaneously exhibiting relatively little or no anity towards wt p53, the most well characterized of these being certain members of the heat shock protein family (Chen et al., 1994; Merrick et al., 1996) . Although not directly shown, the oncogenic synergy between MBP1 and the H175 mutant is likely due to interaction between both proteins. The functional synergy between both full-length MBP1 and mutant p53 with respect to the promotion of tumour cell growth and neoplastic transformation provides indirect evidence for an interaction-based mechanism. The similarity in oncogenic potential (inherent and synergistic) between full-length and N-terminal deleted forms of MBP1 further supports this type of mechanism, as MBP1DN clearly can interact with the H175 mutant in intact mammalian cells. It is not yet clear, however, which protein regulates which in terms of oncogenic potential. Despite this, we propose that MBP1 may play a role in determining if a`gain of function' eect is seen with certain p53 mutants.
Central to understanding how the mutant p53-MBP1 interaction may occur is knowing which protein tracking pathway MBP1 actually follows. As a type I membrane protein, MBP1 would be readily available for interaction with mutant p53 due to exposure of its C-terminus into the cytosol. Even if MBP1 turns out to be a secreted protein, one can easily envisage scenarios in which mutant p53 could interact. For example, the secretory pathway of MBP1 may be disrupted in certain tumour cells, thus opening à window of opportunity' for possible interaction with mutant p53. Indeed, a variety of pathogenic disorders have been linked to defects in protein tracking (Delahunty and Bonifacino, 1995) . Thus, the rather serendipitous nature in which the truncated form of MBP1 was found could be prove to our advantage. Alternatively, mutant p53 may enter into the lumen of the endoplasmic reticulum, or other subcellular organelles, and interact with MBP1 there. There is precedent for this type of mechanism, as mutant p53 has been previously shown to bind to the mitochondrial and endoplasmic reticular chaperones, GRP75 and GRP78 respectively (Merrick et al., 1996) . It is useful to note that the presence of the putative TS does not appear to interfere with the oncogenic synergy between MBP1 and H175. This, as indicated above, provides indirect support for an interaction between full-length MBP1 and mutant p53.
The oncogenic activity of MBP1 in the absence of the H175 mutant is intriguing, re¯ecting an inherent mutant p53-independent role for MBP1 in cell growth regulation. Other constituents of the ®bulin gene family have displayed growth regulatory functions and may also be involved in the tumorigenic process. S1-5 was originally identi®ed on the basis of being an overexpressed gene transcript within senescent human diploid ®broblasts (HDF) (Lecka-Czernik et al., 1995) . Expression of S1-5 mRNA was subsequently shown to be induced during growth arrest of young normal HDF. In contrast, microinjection of S1-5 mRNA into young normal HDF stimulated rather than inhibited DNA synthesis. Additionally, upregulation of S1-5 mRNA was observed in a range of transformed cell lines by comparison with normal controls. Thus, S1-5 appears to be a negative and/or positive cell growth regulatory factor, whose exact function is perhaps dependent on which splice form is expressed. On the other hand, ectopic overexpression of ®bulin-1 in tumour cell line models has been shown to delay tumour formation in vivo and suppress anchorage-independent cell growth, motility and invasion in vitro (Qing et al., 1997; Hayashido et al., 1998) . However, the idea that ®bulin-1 is the product of a tumour suppressor gene is complicated by the recent observation of an accumulated level of ®bulin-1 protein in the stroma of human ovarian carcinomas in comparison to normal ovaries (Roger et al., 1998) . These apparent ambiguities with respect to the involvement of ®bulin gene family members in growth regulation and tumorigenesis need to be resolved.
Entering the arena as the protein product of a candidate oncogene, MBP1 will be a useful extra tool in the exploration of the functions displayed by this emerging gene family. Furthermore, MBP1 provides some new insight with respect to the mutant p53`gain of function' phenotype, a phenomenon which is awaiting clear de®nition.
Materials and methods
Cell lines
The human lung carcinoma cell line, H1299 (p53null; Mitsudomi et al., 1992) , was grown as a monolayer culture in Dulbecco's medium supplemented with 10% heatinactivated foetal calf serum (FCS). REF were grown in the same medium but with 10% normal FCS. Both cell types were kept in 95% air/5% CO 2 at 378C and routinely monitored for Mycoplasma contamination.
Yeast two-hybrid screen
Full-length wt p53 cDNA was ampli®ed by PCR from a human placenta cDNA library (Clontech, Palo Alto, CA, USA). The resulting PCR product was introduced into the pCRII cloning vector (Invitrogen, Carlsbad, CA, USA) and correct sequence con®rmed. Mutant p53 cDNA species (H175, W248, H273 and G281) were generated by sitedirected mutagenesis using the Sculptor system (Amersham International, Buckinghamshire, UK) and oligonucleotide primers containing the desired mutation. Each of the fulllength p53 cDNA forms were introduced into pPC86, a GAL4(TA) yeast two-hybrid expression vector (Chevray and Nathans, 1992) . D1 ± 72 forms were ampli®ed by PCR from respective full-length wt and mutant p53 cDNAs. These truncated p53 variants, as well as the isolated MBP1DN clone and the appropriate portion of GAP cDNA (see Table 1 ), were placed into the GAL4(DB) yeast two-hybrid expression vector pPC97, which is an improved version of the pPC62 vector (Chevray and Nathans, 1992) . Regarding the twohybrid screening procedure, yCM17 cells were initially transformed with the pPC97-H175D1 ± 72 plasmid using the lithium acetate method (Gietz et al., 1995) . The resulting strain was transformed with either 500 mg of the human osteosarcoma MATCHMAKER cDNA expression library (Clontech), or 200 mg of the previously described pPC51-mouse embryo cDNA expression library, otherwise known as pPC67 (Chevray and Nathans, 1992) . To assess proteinprotein interaction, co-transformants were grown in the absence of uracil and examined for bgal activity according to established procedures (Fields and Song, 1989) .
Northern blot analysis
MBP1 and GAPDH-speci®c probes were generated by PCR using DNA originating from the isolated MBP1DN clone and a SuperScript human testis cDNA library (Gibco ± BRL, Paisley, UK), respectively. The following oligonucleotide primers were utilized:
PCR-derived probes were radiolabelled with a 32 P-dCTP using the Rediprime kit (Amersham International). Removal of unincorporated, labelled nucleotides was accomplished through the use of MicroSpin G-25 columns (Pharmacia Biotech, Uppsala, Sweden). Blots were prehybridized with ExpressHyb solution (Clontech) for 45 min at 658C, incubated with radiolabelled probe for 2 h at the same temperature and then washed with 26SSC (three times), 26SSC/0.1% SDS (twice) and 0.26SSC/0.1% SDS (until background became negligible), respectively. Hybridization was quanti®ed by electronic autoradiography using an Instant Imager plus associated software (Packard, Meriden, CT, USA).
Immunoprecipitation MBP1DN and SAM68 were cloned into the expression vector pBFA107, which is derived from the pSV2 vector and encodes a myc epitope at the N-terminus of expressed proteins. Both wt p53 and the various p53 mutants were introduced into the native pSV2 vector. H1299 cells were seeded at 10 6 cells/10 cm plate and transfected 24 h later with the aid of LipofectAmine (Gibco ± BRL) at a ®nal concentration of 8 mg/ml in serum-free medium. A total of 6 mg plasmid DNA was transfected, the amount of DNA introduced split evenly between pSV2-driven expression plasmids. After a 4 h incubation period, complete medium was re-added to the transfected cells. The next day, the cells were lysed at 48C using HNTG lysis buer [50 mM HEPES (pH 7.5), 150 mM NaCl, 1.0% Triton X-100, 10% glycerol] containing protease inhibitors. Cell extracts were incubated with the appropriate antiserum and protein G-Sepharose beads. After washing with cell lysis buer, the beads were boiled in standard SDS sample buer and loaded onto 10% SDS-polyacrylamide gels. Proteins were electroblotted onto PVDF membranes (Novex, San Diego, CA, USA), which were subsequently probed with speci®c antibodies according to conventional protocols.
REF transformation assay
REF were prepared from pregnant Fisher 344 rats carrying embryos of 14 days gestation as previously described (Finlay, 1995) . The complementation assay was performed as before using a total of 20 mg plasmid DNA (Finlay, 1995) , one quarter of which being due to the drug selection plasmid pSV2-NEO (with the rest coming from pSV2-driven expression plasmids). The expression vectors containing for the ras-V12 and c-myc genes have been referred to before (Finlay, 1995) . Early passage REF were seeded at 5610 5 cells/10 cm plate, transfected the next day using the CellPhect kit (Pharmacia Biotech) according to the manufacturer's instructions. Twenty-four hours after transfection, the cells were divided into three 10 cm plates and left for 14 days, at which point foci appeared.
Clonogenic survival assay
H1299 cells were seeded at 10 5 cells/well within 6-well plates and transfected in a similar manner to that mentioned above. A total of 1.5 mg of plasmid DNA was transfected, which includes 300 ng of pSV2-NEO plus the indicated combinations of the dierent pSV2-driven expression constructs. The following day, the cells within each well were trypsinized, divided into two 10 cm plates and grown in the presence of complete medium containing 400 mg/ml G418 (Gibco ± BRL). Two weeks later, surviving colonies were stained with 5% Ziehl-Neelsen's carbol-fuchsin solution and counted in a blinded fashion.
Cloning of full-length MBP1
The N-terminus of MBP1 was cloned by PCR ampli®cation from a SuperScript 8.5 day mouse embryo cDNA library (Gibco ± BRL). The oligonucleotide primers used were as follows:
SP6 ± library 5'-AGCTATTTAGGTGACACTATAG-3' (sense) MBP1 ± middle 5'-CGGTACTGGCAGAGGTAACTGG-3' (antisense) PCR products from four independent ampli®cation reactions were placed into the pCRII vector. Each of these products were sequenced several times in order to prevent erroneous interpretation of the consensus nucleotide sequence. All products were identical with no apparent PCR-derived errors. The N-terminal portion of MBP1 was then joined with MBP1DN using the restriction enzymes EcoRI, PstI and NotI. Once generated, full-length MBP1 cDNA was cloned into the pSV2 vector. The sequence of the isolated MBP1 mRNA transcript, including the 5' and 3' untranslated regions, has been deposited into the GenBank database (accession AF104223).
